Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock Has Consensus Price Target of $33.07

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been assigned an average rating of “Moderate Buy” from the sixteen analysts that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $33.07.

A number of analysts have commented on DYN shares. TD Cowen assumed coverage on Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. JPMorgan Chase & Co. cut Dyne Therapeutics from a “neutral” rating to an “underweight” rating and lowered their price objective for the company from $17.00 to $10.00 in a research report on Wednesday, September 9th. Morgan Stanley cut their target price on Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating for the company in a research note on Wednesday, September 9th. Robert W. Baird cut their target price on Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research note on Wednesday, September 9th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $37.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 8th.

Dyne Therapeutics Stock Down 4.1%

Shares of DYN opened at $15.30 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02. The company has a 50-day simple moving average of $21.16 and a 200-day simple moving average of $20.45. Dyne Therapeutics has a 52 week low of $13.88 and a 52 week high of $27.31. The firm has a market capitalization of $2.86 billion, a P/E ratio of -4.59 and a beta of 1.12.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Wednesday, July 29th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, equities research analysts expect that Dyne Therapeutics will post -3.59 earnings per share for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 2,160,516 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the transaction, the director directly owned 428,946 shares of the company’s stock, valued at approximately $10,723,650. This trade represents a 83.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Cox sold 5,658 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total transaction of $106,823.04. Following the completion of the sale, the chief executive officer directly owned 357,507 shares in the company, valued at approximately $6,749,732.16. The trade was a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 2,598,706 shares of company stock worth $65,432,671. Corporate insiders own 9.46% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its holdings in shares of Dyne Therapeutics by 63.2% during the third quarter. GAMMA Investing LLC now owns 1,882 shares of the company’s stock valued at $30,000 after acquiring an additional 729 shares during the period. NewEdge Advisors LLC bought a new position in Dyne Therapeutics during the 2nd quarter valued at about $300,000. Nykredit A S bought a new position in Dyne Therapeutics during the 2nd quarter valued at about $113,000. Moore Capital Management LP lifted its holdings in Dyne Therapeutics by 288.2% during the 2nd quarter. Moore Capital Management LP now owns 305,794 shares of the company’s stock valued at $6,792,000 after purchasing an additional 227,029 shares during the last quarter. Finally, Two Sigma Securities LLC acquired a new position in Dyne Therapeutics in the second quarter valued at about $222,000. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing genetic medicines for serious neuromuscular diseases. The company’s research is centered on its FORCE platform, which is designed to use targeted antibodies to deliver oligonucleotide-based therapies to skeletal muscle and other relevant tissues.

Dyne’s development programs include DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.